Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions

NCT07670234 | Recruiting DMC

• 2 other identifiers: ONCOSUPP-2026-08CE/UM6SS/18/2025
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies. The main questions it aims to answer :

• What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile?
• Are there any potential drug interactions between dietary supplements and anticancer medications? Participants will:
• Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics.
• Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication).
• Report any perceived adverse effects related to dietary supplement use to assess tolerance.
• Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.

Conditions

Cancer (Solid Tumors); Interaction Drug Food

Keywords

dietary supplements; cancer; Anticancer Therapy

Outcome Measures

Primary Outcomes (2)

• Prevalence of Dietary Supplement Use and Tolerance

  Assessment of the prevalence of dietary supplement use among cancer patients and evaluation of adverse effects associated with dietary supplement consumption.

  At enrollment

• Potential Drug-Supplement Interactions

  Assessment of potential interactions between dietary supplements and anticancer medications

  At enrollment or single study visit

Secondary Outcomes (1)

• Potential Drug-Supplement Interactions Assessed by Artificial Intelligence

  At enrollment or Single study visit

Study Arms (1)

Cancer Patients Using Dietary Supplements

Behavioral: Dietary Supplement Use Assessment

Interventions

Dietary Supplement Use Assessment BEHAVIORAL

Participants will complete a structured face-to-face questionnaire on dietary supplement use, reasons for Use, frequency and duration of use, perceived adverse effects, and concomitant anticancer treatments.

Cancer Patients Using Dietary Supplements

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients diagnosed with cancer and receiving medical anticancer treatment (chemotherapy, hormone therapy, immunotherapy, or targeted therapy) at the study site. Participants will be assessed for dietary supplement use, tolerance, and potential interactions between dietary supplements and anticancer medications.

You may qualify if:

• Patients diagnosed with cancer and receiving medical anticancer treatment, including chemotherapy, hormone therapy, immunotherapy, and targeted therapies.
• Current or recent use of one or more dietary supplements (e.g., vitamins, minerals, herbal products, or other nutritional supplements).
• Adult patients : \>=18

You may not qualify if:

• Patients unable to complete the study questionnaire because of cognitive impairment or a deteriorated health condition.
• Failure or refusal to provide written informed consent.

Sponsors & Collaborators

• Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI): lead

Study Sites (1)

Institut National d'Oncologie

Rabat, Morocco

RECRUITING

MeSH Terms

Conditions

Neoplasms

Central Study Contacts

Sihame Lkhoyaali, Professor of Medical Oncology

CONTACT

+212 668-270035; slkhoyaali@cm6.ma

Badiaa Batlamous

CONTACT

+212 693572066

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Medical Oncology

Study Record Dates

• First Submitted: June 19, 2026
• First Posted: June 26, 2026
• Study Start: June 1, 2025
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): December 31, 2027
• Last Updated: June 26, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

MO (1)